Prof. Einar Stefansson, Oculis’ chairman and co-founder, gave a honorary key note lecture at The Nordic Ophthalmology Congress in Denmark June 8-12, 2016 and received the biennial gold medal for his contribution to eye research. The lecture included Oculis’ break through nanotechnology that delivers drug molecules in eye drops to the back of the eye and offers noninvasive drug therapy for retinal diseases.
Dr. Stefansson received a degree in medicine from University of Iceland Medical School and a Ph.D. degree from Duke University followed by residency and faculty position at Duke. He has served as Vice Dean and Dean of the Faculty of Medicine at the University of Iceland and served as Professor and Chair of the Department of Ophthalmology at the National University Hospital Iceland for the past 25 years. He has co-founded four biotechnology firms in addition to Oculis, including Cyclops which was acquired by DeCode Genetics in 2000.
Dr. Stefansson is chief editor of Acta Ophthalmologica since 2005, on the editorial board of Ophthalmologica, senior advisor of EVER and former board member of EURETINA and Club Jules Gonin. Dr. Stefansson is president of EU-EYE, The European Alliance for Ophthalmology and Eye Research. He is former fellow of the American Academy of Ophthalmology and fellow of ARVO, EVER, Michaelson Club and the Icelandic Ophthalmological Society. He has published more than 200 peer reviewed international publications, more than 400 abstracts, numerous book chapters and patents.
Dr. Stefansson was knighted by the President of Iceland in 2007, received Iceland’s highest award in science in 2008, gave the Jules Gonin lecture in 2008, received the Synsfonden award in Denmark in 2006 and was elected to the European Academy of Ophthalmology (with gold medal) in 2009. He has received the Mooney Medal of the Irish College of Ophthalmology (2012) and Bjerrum medal of the Danish Ophthalmological Society (2014) among other honours. In 2016 he received the biennial Gold Medal and gave The Acta Ophthalmologica hononary lecture at the Nordic Ophthalmology Congress.
Oculis (http://www.oculispharma.com) is a clinical-stage, privately held, pharmaceutical development company focusing on ophthalmic drugs and novel drug delivery to the eye. Oculis has developed the solubilizing nanoparticle (SNP) drug delivery platform consisting of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The SNP platform provides sustained release over several hours and allows for greatly increased solubility of lipophilic drugs. Among the key advantages of the SNP platform is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application, i.e. an eye drop.